MRG-001 in Patients With Alcoholic Hepatitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-01

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to test MRG-001 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of MRG-001 in patients with severe alcoholic hepatitis (AH).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of F-652 in Patients With Alcoholic Hepatitis

NCT02655510

Alcoholic Hepatitis

COMPLETED PHASE1/PHASE2

MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease

NCT04116242

Liver Disease Cirrhosis of the Liver Acute-On-Chronic Liver Failure +1 more

COMPLETED

Sensitivity of Alternative NRL972 Detection Methods in Healthy Subjects

NCT01164332

Cirrhosis

COMPLETED PHASE1

Clinical Study of Hepatocyte Transplantation for Liver Cirrhosis

NCT04806581

Liver Cirrhosis

UNKNOWN PHASE1

LiverTREM-1: Hepatic TREM-1 Expression and Prognosis in Severe Alcoholic Hepatitis

NCT07176741

Severe Alcoholic Hepatitis

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcoholic Hepatitis Acute Alcoholic Hepatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MRG-001 (0.005 mL/kg)

Lowest dose of dose-escalation arm

Group Type EXPERIMENTAL

MRG-001

Intervention Type DRUG

Patients will receive subcutaneous administration of MRG-001 at designated visits.

MRG-001 (0.007 mL/kg)

Intermediate dose of dose-escalation arm

Group Type EXPERIMENTAL

MRG-001

Intervention Type DRUG

Patients will receive subcutaneous administration of MRG-001 at designated visits.

MRG-001 (0.01 mL/kg)

High dose of dose-escalation arm

Group Type EXPERIMENTAL

MRG-001

Intervention Type DRUG

Patients will receive subcutaneous administration of MRG-001 at designated visits.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRG-001

Patients will receive subcutaneous administration of MRG-001 at designated visits.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Informed Consent: Able to provide written informed consent, either personally or through a legally acceptable representative.
2. Male or female patients 21 years of age or older.
3. Onset of jaundice within the prior 8 weeks.
4. Alcohol Consumption: Average daily consumption of more than 40 grams for females or more than 60 grams for males of alcohol for 6 months or longer, with less than 8 weeks of abstinence before the onset of jaundice.
5. Diagnostic Criteria for AH: AH may be diagnosed based on typical serum chemistry or liver biopsy during the current episode of AH, including:

* Serum bilirubin \> 3 mg/dL
* AST between 50 and 400 IU/L
* ALT \< 400 IU/L
* AST/ALT ratio \> 1.5
6. Maddrey Discriminant Function (MDF): MDF ≥ 32, assuming a control prothrombin time of 12 seconds.
7. Model for End-stage Liver Disease (MELD) Score: MELD score between 21 and 30.
8. Liver Biopsy (Optional): Liver biopsy is not required but may be used to confirm the diagnosis of AH at the Investigator's discretion. If used, the biopsy must have occurred during the current episode.
9. Contraception for Women: Women of childbearing potential must use appropriate birth control throughout the study duration. Contraception for Men: Male patients must agree to use a medically acceptable method of contraception or birth control throughout the study duration.

Exclusion Criteria

1. Informed Consent: Inability to provide written informed consent, either personally or through a legally acceptable representative.
2. Participation in Other Clinical Trials: Participation in another interventional clinical trial (drug or device) within 30 days of screening and at any time during the study.
3. Concomitant Liver Diseases: Presence of other concomitant causes of liver disease, such as viral hepatitis, autoimmune liver disease, metabolic liver disease, or vascular liver disease.
4. Liver Biopsy Incompatibility: Liver biopsy findings, if conducted, not compatible with alcoholic hepatitis (AH).
5. Absence of Active Infection: No evidence of active infection as determined by the investigator, with specific criteria outlined for diagnosing and treating infections.
6. Uncontrolled Gastrointestinal Bleeding: Presence of uncontrolled gastrointestinal bleeding.
7. History of pre-admission refractory ascites, as defined by the frequency of paracenteses despite diuretic therapy.
8. Significant pre-existing organ dysfunction in various systems, including lung, heart, kidney, hematologic, neurological, and spleen-related conditions.

1. Lung: Receiving supplemental home oxygen therapy at baseline for pre-existing medical condition (other than COVID-19), as documented in medical record.
2. Heart: Pre-existing congestive heart failure defined as an ejection fraction \<20% as documented in the medical record. Clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), unstable angina, myocardial infarction (past 3 months), heart and coronary vessel surgery (past 3 months), significant valvular heart disease, uncontrolled arterial hypertension with systolic blood pressure \>180 mm Hg and diastolic blood pressure \>110 mm Hg.
3. Renal: End-stage renal disease requiring renal replacement therapy or creatintine clearance \<30 mL/min.
4. Hematologic: Baseline platelet count \<30,000/mm3 or hemoglobin levels \<6.0 g/dL.
5. Neurological: Stage ≥3 hepatic encephalopathy by West Haven criteria.
6. History of splenectomy or splenomegaly (spleen weighing \> 750 g).
9. Presence of any active malignancy or malignancy diagnosed within the last five years, excluding curable skin cancer.
10. Patients requiring the use of vasopressors or inotropic support, excluding stabilized conditions within the first 7 days of hospital admission.
11. Presence of co-infection with human immunodeficiency virus (HIV) or active tuberculosis on chest X-ray at study entry.
12. History of organ or bone marrow transplantation, excluding corneal transplant, or recent chronic use of immunosuppressive drugs.
13. Positive urine drug screen for specific substances, excluding THC and prescription medications.
14. Hypersensitivity to either of the components of MRG-001.
15. If female, known pregnancy, positive serum pregnancy test, or lactating/breastfeeding.
16. Underlying diseases that might be complicated or exacerbated by proposed treatments or confound assessment of study drug, as determined by the site investigator.

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No